Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Caspofungin bests fluconazole for antifungal prophylaxis in young AML patients

Publish date:: November 5, 2019

Key clinical point: Antifungal prophylaxis with caspofungin was better than fluconazole in children and young adults with acute myeloid leukemia (AML) at risk of invasive fungal disease.

Major finding: At 5-month follow-up, the cumulative incidence rate of probable or proven invasive fungal disease was significantly lower in the caspofungin arm (3.1%) compared with the fluconazole arm (7.2%).

Study details: A randomized clinical study of 517 children and young adults with AML.

Disclosures: The National Cancer Institute funded the study. The authors reported financial affiliations with Astellas, Celgene, Leadiant Biosciences, Merck, Nabriva Therapeutics, Novartis, Pfizer, Shire, and T2 Biosystems.

Citation:

Fisher BT et al. JAMA. 2019;322(17):1673-81.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in AML

Beat AML: Precision medicine strategy feasible, superior to SOC for AML,

Survey quantifies COVID-19’s impact on oncology,

Combo drug improves survival in older patients with high-risk/secondary AML,

Venetoclax plus LDAC tops LDAC alone in AML,

Azacitidine plus enasidenib improves response, but not survival, in mIDH2 AML,